tbuckley/cabot-search huggingface dataset:
MA15.09 Response to the Treatment Immediately before Nivolumab Monotherapy May Predict Clinical Response to Nivolumab
Authors: Haruki Kobayashi, Shota Omori, Kazuhisa Nakashima, Kazushige Wakuda, Akira Ono, Hirotsugu Kenmotsu, Tateaki Naito, Haruyasu Murakami, Masahiro Endo, Toshiaki Takahashi
Journal: Journal of Thoracic Oncology (2017)
Remarkable Activity of Bortezomib Combined with Chemotherapy in a Phase I Study of Relapsed Childhood Acute Lymphoblastic Leukemia (ALL). A Report from the Therapeutic Advances in Childhood Leukemia (TACL) Consortium.
Authors: Yoav H. Messinger, Paul S. Gaynon, Elizabeth Raetz, Raymond Hutchinson, Steven DuBois, Julia Glade Bender, Richard Sposto, Jeannette van der Giessen, Elena Eckroth, Bruce C. Bostrom
Journal: Blood (2008)
Immunisation against Human c-MYC Elicits a T-Cell Response and Influences Growth of High Grade B-Cell Lymphoma in Mice.
Authors: Florian Helm, Andrea Wilke, Thomas Kammertoens, Christian Friese, Josef Mautner, Christoph Loddenkemper, Georg Bornkamm, Armin Gerbitz
Journal: Blood (2009)
P2.02-009 Clinical Outcomes of Induction Chemoradiotherapy with High Dose Chest Radiation for Locally Advanced Non-Small Cell Lung Cancer Patients
Authors: Hidejiro Torigoe, Shinichi Toyooka, Kazuhiko Shien, Junichi Soh, Hiromasa Yamamoto, Kentaro Miyoshi, Seiichiro Sugimoto, Masaomi Yamane, Takahiro Oto, Kuniaki Katsui, Katsuyuki Hotta, Susumu Kanazawa, Katsuyuki Kiura, Shinichiro Miyoshi
Journal: Journal of Thoracic Oncology (2017)
Whole Genome Sequencing Reveals Novel Recurring Somatic Mutations Affecting HUWE1 and DIAPH2 Genes in Multiple Myeloma
Authors: Michael H. Tomasson, Dong Shen, Vishwanathan Hucthagowder, William Schierding, Chelsea D. Mullins, Mark Fiala, Ira M Hall, John Wallis, Robert S. Fulton, Lucinda A. Fulton, Shashikant Kulkarni, Elaine R. Mardis, Richard K Wilson, Timothy J. Ley, John F. DiPersio, Christopher A. Maher, Ravi Vij, Li Ding
Journal: Blood (2012)
P10 Light may be used to differentiate mesothelioma from benign pleural disease at the bedside
Authors: NK Oswald, A Robertson, P Rajesh, R Steyn, E Bishay, M Kalkat, B Naidu
Journal: Thorax (2016)

<h3>Introduction</h3> Monitoring patients at risk of mesothelioma, earlier diagnosis and improving diagnostic tests are top research priorities set by the James Lind Alliance. Chest wall motion (CWM) can be quantified using structured light plethysmography (SLP). During SLP a single source of visible light projects a chequerboard grid onto the anterior chest wall of a patient; two spaced cameras record changes in the contours of the grid to calculate thoracic volume changes. This study aimed to assess whether there are quantifiable differences in CWM between benign pleural disease and mesothelioma using SLP. <h3>Methods</h3> Patients attending the preoperative assessment clinic for an elective diagnostic pleural biopsy were prospective recruited. After giving consent, patients underwent a timed 5 minute SLP recording of tidal breathing whilst resting in an upright seated position. Recordings were done prior to surgery and analysis of the SLP recording was performed by a blinded technician. Histology results were collected after surgery and Mann Whitney U two tailed tests of SLP values performed. <h3>Results</h3> Fifteen patients were recruited with a median age 71 (23–93 range), 90% were male. Patients subsequently diagnosed with mesothelioma (n = 4) had significantly different values in three measurements: the inspiratory to expiratory time ratio (Ti/Te, p = 0.009), breath phase between ribcage and abdomen (breath phase RC2AB, p = 0.013) and the variation in ratio of inspiratory flow at 50% of tidal motion to expiratory flow at 50% of tidal motion (IE50 IQR, p = 0.004). Median and interquartile ranges for breath phase (a measure of CWM synchrony) are shown in Figure 1. The recording process was highly acceptable to patients. <h3>Conclusions</h3> Mesothelioma affects the ratio of time for inspiration and expiration as well as synchrony in CWM and variability of the breathing pattern. SLP is rapid, portable, non-invasive, requires minimal operator training and involves no radiation. The differences found indicate that CWM measurement is a promising tool to diagnose or exclude mesothelioma and potentially to monitor patients at risk of mesothelioma, further studies using SLP in this context are indicated.
S2 Fractional exhaled nitric oxide (feno) suppression to identify non-adherence in difficult asthma
Authors: KJ Hetherington, RW Costello, LG Heaney
Journal: Thorax (2016)

<h3>Introduction</h3> Non-adherence, both intentional and non-intentional, is prevalent in ‘difficult to manage’ asthma and identification of patients who should respond to inhaled corticosteroids (ICS) is essential to reduce exacerbation risk and improve asthma control, but also to prevent inappropriate escalation of treatment (oral corticosteroids or biological therapies). Composite biomarker assessments (FeNO and blood eosinophils) have been shown to predict exacerbation risk in patients with asthma and these biomarkers also predict response to steroid treatment. It has previously been demonstrated that suppression of FeNO with directly observed ICS over 7 days can identify non-adherence to ICS treatment. The aim of this work was to further validate this test across UK severe asthma centres in the RASP-UK Consortium and to examine if the test can identify patients who should achieve good asthma control with better adherence to ICS treatment. <h3>Methods</h3> Using remote monitoring technology (Vitalograph INCA™ device and Aerocrine NIOX Vero), we developed a web-based interface to deliver FeNO suppression testing in RASP-UK Severe Asthma Centres. We examined the utility of FeNO suppression testing to predict inhaled steroid responsiveness and composite biomarker profile after 30 days of monitored optimised treatment on standard high dose ICS/LABA. <h3>Results</h3> Forty of seventy patients had a positive suppression test. Using information from the Vitalograph INCA™ server to highlight technique and timing errors, these issues were addressed and patients proceeded to 30-day monitoring of high dose ICS/LABA. A positive FeNO suppression test (Figure A) identified a biomarker-low population when adherent with high dose ICS (≥80% of inhaled steroid) whereas a negative test (Figure B) identified a biomarker-high population when adherent with high dose ICS. <h3>Conclusion</h3> FeNO suppression testing is an effective means of identifying non-adherence to inhaled steroids in patients with difficult to manage asthma. This test can identify patients who should be optimised on inhaled steroids prior to consideration of treatment escalation. <h3>Collaborating Centres</h3> Queen’s University Belfast, University of Leicester, University of Glasgow, University of Oxford, The University of Manchester, University of Birmingham, University College London.
A multiplex technology platform for the rapid detection of relevant mutations in the EGFR signaling pathway.
Authors: E. Labourier, D. Smith, W. Laosinchai-Wolf, L. Friar, J. Houghton, A. Hadd, G. Latham
Journal: Journal of Clinical Oncology (2011)

386 Background: Determination of the mutational status of key gene effectors along the EGFR signaling pathway plays a critical role in the management of metastatic colorectal cancer (mCRC) and other cancer types. We previously reported the rapid, multiplex, and sensitive detection of 7 common KRAS mutations in mCRC FFPE specimens using the Signature KRAS Mutations (RUO) kit. We show here that the same technology platform can be applied to the detection of additional clinically relevant mutations in the EGFR, BRAF, KRAS, NRAS and HRAS genes. Methods: Mutation panels were designed for multiplex PCR amplification of an internal control gene and discrete mutation regions in independent target genes. PCR products were hybridized on a liquid bead array carrying target-specific probes and sorted by flow cytometry using a Luminex 200 system. Genomic DNA was extracted from cell lines and representative flash frozen, FFPE or FNA clinical specimens using laboratory-validated extraction methods. Results: Using model plasmids and cell lines we developed specific assays for distinct mutations in KRAS codon 12/13, KRAS 3' UTR (rs61764370), BRAF codon 600/601, HRAS codon 12/61, NRAS codon 61, and EGFR exon 19/20/21. The various assays reached 0.1 to 5% analytical sensitivity and could be further combined in multiplex panels relevant to specific applications. The Signature KRAS/BRAF Mutations (RUO) kit, an assay for 12 KRAS mutations in codon 12/13 and BRAF V600E, was validated in over 250 mCRC FFPE specimens with &gt;99% agreement with clinically validated methods. Specific detection of these 13 mutations and 6 HRAS/NRAS mutations was also demonstrated in thyroid nodule FNA specimens. Single-well detection of EGFR deletions in exon 19 together with the point mutations L858R and T790M was also successfully evaluated in lung specimens. Conclusions: The Signature technology platform is a specific, sensitive and flexible tool for the assessment of various mutations in different tissue types. The development and validation of broader mutation panels would likely facilitate the rapid molecular characterization of individual tumor specimens and the optimization of personalized treatments for mCRC and other cancer types. [Table: see text]
Treatment of Elderly Patients with Acute Myeloid Leukemia Adjusted to Age, Performance Status, Organ Function and the Presence of Co-Morbidities. Final Results of the Polish Adult Leukemia Group (PALG) 1/2005 Study.
Authors: Bozena Katarzyna Budziszewska, Agnieszka Pluta, Kazimierz Sulek, Tadeusz Robak, Sebastian Giebel, Aleksandra Holowiecka, Waldemar Sawicki, Anna Ejduk, Elzbieta Patkowska, Joanna Manko, Justyna Gajkowska-Kulik, Jaroslaw Piszcz, Monika Mordak-Domagala, Jerzy Holowiecki, Slawomira Kyrcz-Krzemien, Krzysztof Warzocha, Maria Domagala, Anna Dmoszynska, Malgorzata Calbecka, Janusz Kloczko, Kazimierz Kuliczkowski, Wieslaw Wiktor Jedrzejczak, Andrzej Lange, Malgorzata Razny, Agnieszka Wierzbowska
Journal: Blood (2010)
Versatile humanized niche model enables study of normal and malignant human hematopoiesis
Authors: Ander Abarrategi, Katie Foster, Ashley Hamilton, Syed A. Mian, Diana Passaro, John Gribben, Ghulam Mufti, Dominique Bonnet
Journal: Journal of Clinical Investigation (2017)

The BM niche comprises a tightly controlled microenvironment formed by specific tissue and cells that regulates the behavior of hematopoietic stem cells (HSCs). Here, we have provided a 3D model that is tunable in different BM niche components and useful, both in vitro and in vivo, for studying the maintenance of normal and malignant hematopoiesis. Using scaffolds, we tested the capacity of different stromal cell types to support human HSCs. Scaffolds coated with human mesenchymal stromal cells (hMSCs) proved to be superior in terms of HSC engraftment and long-term maintenance when implanted in vivo. Moreover, we found that hMSC-coated scaffolds can be modulated to form humanized bone tissue, which was also able to support human HSC engraftment. Importantly, hMSC-coated humanized scaffolds were able to support the growth of leukemia patient cells in vivo, including the growth of samples that would not engraft the BM of immunodeficient mice. These results demonstrate that an s.c. implantation approach in a 3D carrier scaffold seeded with stromal cells is an effective in vivo niche model for studying human hematopoiesis. The various niche components of this model can be changed depending on the context to improve the engraftment of nonengrafting acute myeloid leukemia (AML) samples.
P3.02c-089 ImmunoCHIC: A Prospective Nivolumab Monotherapy Cohort in Advanced Non-Small Cell Lung Cancer Patients in Routine Clinical Practice
Authors: Shobanya Elvarathnam, Christos Chouaid, Nadine Thiriat., Laurence Jabot, Gaelle Rousseau-Bussac, Caroline Jaskowiec, Florent Vinas, Stephanie Poullain, Isabelle Monnet
Journal: Journal of Thoracic Oncology (2017)
CD24 aggravates acute liver injury in autoimmune hepatitis by promoting IFN-γ production by CD4+ T cells
Authors: Chenhong Zheng, Shulei Yin, Yang Yang, Yizhi Yu, Xiaohua Xie
Journal: Cellular and Molecular Immunology (2017)

The T-cell-mediated immune response is implicated in many clinical hepatic injuries, such as autoimmune hepatitis and acute virus hepatitis. CD24 is widely expressed by different immune cells and plays an important role in the pathogenesis of many autoimmune diseases. However, the role of CD24 in T-cell-mediated liver injury has not been elucidated until now. Here we showed that CD24 deficiency protects mice from concanavalin A (ConA)-induced fulminant liver injury by reducing serum interferon-γ (IFN-γ) levels. CD24 expression by hepatic T cells was markedly increased following ConA challenge. Moreover, decreased IFN-γ production by hepatic CD4+ T cells in CD24-deficient mice was detected, which was correlated with downregulated phosphorylation of STAT1 in hepatic tissue. In vitro experiments also supported the conclusion that CD24 deficiency impaired IFN-γ production by CD4+ T cells following ConA, CD3/CD28 and phorbol myristate acetate/ionomycin stimulation. Our study suggests that CD24 deficiency confers hepatoprotection by decreasing CD4+ T-cell-dependent IFN-γ production in vivo, which suggests that CD24 might be a potential target molecule for reducing clinical hepatitis.
A Novel Functional Polymorphism in the CCAAT/Enhancer Binding Protein (C/EBP), Epsilon (CEBPE) Gene Promoter Influences Acute Lymphoblastic Leukemia Risk Via Interaction with IKZF1
Authors: Kyle M. Walsh, Adam J. de Smith, Jianqiao Xiao, Marcus O. Muench, Marina Fomin, Helen M. Hansen, Catherine Metayer, Joseph L. Wiemels
Journal: Blood (2014)
OA19.01 A Standardized and Validation of Prognostic Gene Expression Signatures for Squamous Cell Lung Carcinoma by the SPECS Lung Consortium
Authors: William Richards, Raphael Bueno, David Beer, Karla Ballman, Ramaswamy Govindan, Ming Tsao, Mark Watson, Daniel Merrick, Adriaan Van Bokhoven, Frances Shepard, David R. Gandara, Wilbur Franklin, David Harpole, Guoan Chen, Zhengming Chen, Lucian Chirieac, Herman Chui, Carlo Genova, Mary-Beth Joshi, Ashley Kowalewski, Mark Onaitis, Christopher Rivard, Thomas Sporn, Fred R. Hirsch
Journal: Journal of Thoracic Oncology (2017)
OA18.02 Evaluation of a Modified Dosing Regimen (2-Weeks on/1-Week off) of Sunitinib as Part of a Phase II Trial in Thymic Carcinoma
Authors: Arun Rajan, Chul Kim, Udayan Guha, Eva Szabo, Arlene Berman, Linda Sciuto, A. John Spittler, Jane Trepel, Seth Steinberg, Pamela Harris, Raffit Hassan, Patrick Loehrer
Journal: Journal of Thoracic Oncology (2017)
Dynamics of influenza-induced lung-resident memory T cells underlie waning heterosubtypic immunity
Authors: Bram Slütter, Natalija Van Braeckel-Budimir, Georges Abboud, Steven M. Varga, Shahram Salek-Ardakani, John T. Harty
Journal: Science Immunology (2017)

Lung-resident memory CD8 T cells (TRM) induced by influenza A virus (IAV) that are pivotal for providing subtype-transcending protection against IAV infection (heterosubtypic immunity) are not maintained long term, causing gradual loss of protection. The short-lived nature of lung TRM contrasts sharply with long-term maintenance of TRM induced by localized infections in the skin and in other tissues. We show that the decline in lung TRM is determined by an imbalance between apoptosis and lung recruitment and conversion to TRM of circulating memory cells. We show that circulating effector memory cells (TEM) rather than central memory cells (TCM) are the precursors for conversion to lung TRM Time-dependent changes in expression of genes critical for lymphocyte trafficking and TRM differentiation, in concert with enrichment of TCM, diminish the capacity of circulating memory CD8 T cells to form TRM with time, explaining why IAV-induced TRM are not stably maintained. Systemic booster immunization, through increasing the number of circulating TEM, increases lung TRM, providing a potential new avenue to enhance IAV vaccines.
Early Onset of Acute Graft-Versus-Host Disease Indicating a Worse Prognosis in Terms of Chronic Graft-Versus-Host Disease and Survival Compared to Late Onset.
Authors: Sang Kyun Sohn, Joon Ho Moon, Jong Gwang Kim, Yee Soo Chae, Yoon Young Cho, Byung Min Ahn, Shi Nae Kim, Soo Jung Lee, Yun Jeong Kim
Journal: Blood (2007)
Influence of Prior Lenalidomide Exposure On Peripheral Blood Progenitor Cell Mobilization for Autologous Stem Cell Transplant in 144 Consecutive Patients with Multiple Myeloma.
Authors: Jason Valent, Nishant Tageja, Jeffrey A Zonder, Richard Manasa, Judith Abrams, Tomoko Avila, Muneer H. Abidi
Journal: Blood (2009)
P3.02b-065 Third Line Therapy in EGFR Positive Advanced Non-Small Cell Lung Cancer
Authors: Nikhil Pande, Amit Joshi, Vanita Noronha, Vijay Patil, Anuradha Chougule, Amit Janu, Sucheta More, Supriya Goud, Ashay Karpe, Anant Ramaswamy, Arun Chandrasekharan, Vikas Talreja, Alok Goel, Kumar Prabhash
Journal: Journal of Thoracic Oncology (2017)
Quitting Smoking Among Adults — United States, 2000–2015
Authors: Stephen Babb, Ann Malarcher, Gillian Schauer, Kat Asman, Ahmed Jamal
Journal: MMWR Morbidity and Mortality Weekly Report (2017)

Quitting cigarette smoking benefits smokers at any age (1). Individual, group, and telephone counseling and seven Food and Drug Administration-approved medications increase quit rates (1-3). To assess progress toward the Healthy People 2020 objectives of increasing the proportion of U.S. adults who attempt to quit smoking cigarettes to ≥80.0% (TU-4.1), and increasing recent smoking cessation success to ≥8.0% (TU-5.1),* CDC assessed national estimates of cessation behaviors among adults aged ≥18 years using data from the 2000, 2005, 2010, and 2015 National Health Interview Surveys (NHIS). During 2015, 68.0% of adult smokers wanted to stop smoking, 55.4% made a past-year quit attempt, 7.4% recently quit smoking, 57.2% had been advised by a health professional to quit, and 31.2% used cessation counseling and/or medication when trying to quit. During 2000-2015, increases occurred in the proportion of smokers who reported a past-year quit attempt, recently quit smoking, were advised to quit by a health professional, and used cessation counseling and/or medication (p<0.05). Throughout this period, fewer than one third of persons used evidence-based cessation methods when trying to quit smoking. As of 2015, 59.1% of adults who had ever smoked had quit. To further increase cessation, health care providers can consistently identify smokers, advise them to quit, and offer them cessation treatments (2-4). In addition, health insurers can increase cessation by covering and promoting evidence-based cessation treatments and removing barriers to treatment access (2,4-6).
Early Trafficking of Bone Marrow Derived-Endothelial Progenitor Cells Promotes Multiple Myeloma Progression
Authors: Michele Moschetta, Yuji Mishima, Yawara Kawano, Yosra Aljawai, Bruno Paiva, Luis Palomera, Arianna Calcinotto, Unitt L. Christine, Ilyas Sahin, Antonio Sacco, Siobhan Glavey, Michaela R. Reagan, Salomon Manier, Peter Leif Bergsagel, Marta Chesi, Matteo Bellone, Aldo M Roccaro, Irene M. Ghobrial
Journal: Blood (2014)
P242 The airway microbiota in human rhinovirus induced asthma exacerbation
Authors: EHC Wong, J Dhariwal, L Cuthbertson, P James, M Cox, M Moffatt, W Cookson, S Johnston
Journal: Thorax (2016)

<h3>Background</h3> Acute asthma exacerbations (AEs) cause significant morbidity. Up to 60% of AEs may be associated with respiratory viral infections, particularly human rhinoviruses (HRVs). The role of bacteria in AEs is unclear, yet antibiotics are frequently prescribed. Recent studies have demonstrated a greater abundance of potentially pathogenic bacteria (e.g. <i>Haemophilus</i> spp.) within the airway microbiota in asthma, whilst a greater abundance of commensals (e.g. <i>Prevotella</i> spp.) were observed in health. The aim of this study was to examine the changes within the airway microbiota in asthma in the context of a HRV-induced AE and evaluate if such changes correlate with clinical symptoms and lung function changes. <h3>Methods</h3> Eleven moderate asthmatic (BTS step 3–4) and 12 healthy subjects were experimentally infected with HRV-16 and bronchoscopy was performed at baseline, 3 and 8 days following HRV-infection. Subjects completed daily symptom diary and spirometry. DNA was extracted from bronchoalveolar lavage and PCR amplification of the V3-V5 region of bacterial 16S rRNA gene was performed to evaluate microbiota community composition. <h3>Results</h3> The microbiota composition did not significantly differ between healthy and asthmatic subjects at baseline, though healthy subjects exhibited significantly greater relative abundance of <i>Prevotella</i> spp. following HRV-infection (p &lt; 0.05). At day 3 post-HRV infection, greater <i>Prevotella</i> spp. relative abundance was associated with lower symptom scores (R2 = 0.56, p &lt; 0.05). In contrast, at day 8 greater <i>Neisseria</i> spp. relative abundance was associated with greater peak flow decline (R2 = 0.41, p &lt; 0.05). Furthermore, HRV-16 viral load exhibited a significant linear relationship with the degree of microbiota community change (as measured by beta-diversity) (R2 = 0.61, p &lt; 0.05). <h3>Conclusion</h3> Following HRV infection, greater <i>Prevotella</i> spp. relative abundance was associated with less symptoms whilst greater <i>Neisseria</i> spp. was associated with greater peak flow decline, suggesting an imbalanced microbiota may exacerbate airway inflammation and ultimately severity of AE. Viral load significantly correlated with degree of microbiota community change, implying HRV infection may directly perturb the airway microbiota. Further studies are needed to confirm these findings and explore the roles of <i>Prevotella</i> spp. and <i>Neisseria</i> spp. in exacerbating airway inflammation.
First Preclinical Report of the Efficacy and PD Results of KHK2823, a Non-Fucosylated Fully Human Monoclonal Antibody Against IL-3Rα
Authors: Tadakazu Akiyama, Shin-ichiro Takayanagi, Yoshimi Maekawa, Kohta Miyawaki, Fumiaki Jinnouchi, Takashi Jiromaru, Takeshi Sugio, Shinya Daitoku, Hirotake Kusumoto, Munetake Shimabe, Satoshi Nishikawa, Kengo Yamawaki, Kousuke Iijima, Masanori Hiura, Takeshi Takahashi, Yoshikane Kikushige, Hiromi Iwasaki, Koichi Akashi, Tomonori Tawara
Journal: Blood (2015)